NO. 032 · STAGE 1 · Lv. 73 · HP 135
CJC-1295
Stabilized GHRH Analog · With/No DAC
ALIASES
CJC-1295, DAC:GRF, Mod GRF 1-29, CJC-1295 No DAC, modified GRF(1-29)
CLASS
Synthetic peptide · stabilized GHRH(1-29) analog (two variants)
FORMULA
C152H252N44O42 (No DAC variant)
SEQUENCE
Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg (No DAC)
HALF-LIFE
~30 minutes (No DAC) · ~1 week (with DAC)
ROUTES
Subcutaneous (research)
MECHANISM OF ACTION
Synthetic 30-amino-acid GHRH(1-29) analog with stabilizing substitutions resisting DPP-IV cleavage. Two variants: with DAC (albumin-binding MPA linker, ~1-week half-life) and No DAC (Mod GRF 1-29, ~30 min half-life). Standard No-DAC stack partner for Ipamorelin.
EVIDENCE GRADES
Teichman et al. 2006 (PMID 16352683) reported sustained IGF-1 elevation for up to 9 days post single-dose.
Animal-model dual-pathway studies; community-reported research protocols.
No published RCT for either variant in body-composition endpoints. ConjuChem with-DAC clinical program halted.
MECHANISM CATEGORIES
RESEARCH CONDITIONS
SAFETY
Side effects
- Injection-site reactions
- Mild flushing
- Headache
- Water retention (more common with-DAC variant)
Known interactions
- Concurrent rhGH not recommended
- Insulin / glucose-lowering agents (mild hyperglycemia possible)
- Glucocorticoids may blunt response
Contraindications
- Active malignancy
- Pituitary tumor
- Pregnancy/lactation
REGULATORY STATUS
FDA · Not FDA-approved. ConjuChem clinical program for the with-DAC variant halted in mid-2000s after two deaths in a lipodystrophy trial. Causality not definitively established.
WADA · Prohibited at all times under WADA Section S2 (GHRH-analog sub-category).
STORAGE
Lyophilized · 4 °C 24 months
Reconstituted · 2-8 °C, 28 days
PEER-REVIEWED EVIDENCE
- Teichman SL, Neale A, Lawrence B, et al.. Prolonged stimulation of growth hormone and IGF-I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab 2006. PMID 16352683. link →
- Sinha DK, Balasubramanian A, Tatem AJ, et al.. Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males. Transl Androl Urol 2020. PMID 32257854. link →
FAQ · 8 QUESTIONS
▶ What is CJC-1295?
CJC-1295 is a synthetic 30-amino-acid analog of growth-hormone-releasing hormone GHRH(1-29) developed by ConjuChem in the 2000s as a long-acting research compound. Two pharmacokinetic variants exist: with DAC (covalent albumin-binding linker, ~1-week half-life) and No DAC (Mod GRF 1-29, ~30-minute half-life).
▶ CJC-1295 vs sermorelin · what's the difference?
Sermorelin is the unmodified native GHRH(1-29) with rapid DPP-IV cleavage. CJC-1295 retains four stabilizing amino-acid substitutions (Ala2→D-Ala, Arg15→Gln, Leu27→Ala, Asp28→Ser) that resist DPP-IV. The No-DAC variant has the same half-life as sermorelin (~30 min) but resists cleavage. The with-DAC variant adds a maleimidopropionic-acid linker for ~1-week half-life.
▶ What is the difference between CJC-1295 with DAC and No DAC?
The DAC (Drug Affinity Complex) variant carries a maleimidopropionic-acid linker that covalently binds plasma albumin in vivo, extending half-life to roughly one week. The No-DAC variant lacks the linker and has the same ~30-min half-life as native GHRH. Most current research uses No DAC; the with-DAC ConjuChem clinical program was halted.
▶ Why was the ConjuChem program halted?
Two deaths occurred during a lipodystrophy clinical trial in the mid-2000s. Subsequent investigation did not definitively establish causality, but the development program was not resumed.
▶ Is CJC-1295 FDA-approved?
No. Neither variant is FDA-approved. Research-use only.
▶ Is CJC-1295 WADA-prohibited?
Yes. CJC-1295 is prohibited at all times under WADA Section S2 in the GHRH-analog sub-category.
▶ Why is CJC-1295 paired with ipamorelin?
CJC-1295 engages the GHRH receptor; ipamorelin engages the ghrelin / GHS-R1a receptor. The two pathways are independent and complementary; combined activation amplifies the GH pulse synergistically.
▶ How is CJC-1295 dosed in research?
Community-reported research protocols use CJC-1295 No DAC at 100-300 mcg per administration, paired 1:1 by mass with ipamorelin, 1-3 times daily, subcutaneous. With-DAC historical protocols used 1-2 mg per week. No human dose is recommended by this wiki.
SIGNATURE MOVES
DPP-IV-resistant. Extended GHRH receptor engagement.
With-DAC variant: albumin tethering. ~1-week half-life.
SOURCED FROM PEPPU LABS
Reference compounds documented on this page are available as research-grade material at Peppu Studio · ≥99% purity · per-batch Certificate of Analysis. For laboratory research use only. No human dose is recommended by this wiki.
▶ LAST UPDATED · 2026-05-25